• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Apixaban in Patients with Atrial Fibrillation and Severe Renal Dysfunction: Findings from a National Registry
CONCLUSIONS: Apixaban might be a reasonable alternative to warfarin in patients with severe renal impairment.PMID:34155848
Source: The Israel Medical Association Journal - June 22, 2021 Category: General Medicine Authors: Avishay Elis Robert Klempfner Chen Gurevitz Ela Gilady Ilan Goldenberg Source Type: research

Appropriateness of non-vitamin K antagonist oral anticoagulant dose in patients with atrial fibrillation in Israel: A population-based study
The non-vitamin K oral antagonists (NOACs) are at least as effective as warfarin in the prevention of stroke in non valvular atrial fibrillation (NVAF) and are associated with less intracranial hemorrhage. Many patients with NVAF inappropriately do not receive anticoagulants often because of the inconvenience associated with warfarin administration. NOACs have the potential to increase anticoagulation use because they are safer and easier to administer than warfarin. Indeed, the use of anticoagulation in patients with newly diagnosed AF in many countries is increasing as a result of the use of NOACs in preference to warfarin [1].
Source: Thrombosis Research - July 24, 2018 Category: Hematology Authors: Martin H. Ellis, Sari Greenberg Dotan, Ariel Hammerman, Erez Battat, Estela Derazne, Orly Avnery Tags: Letter to the Editors-in-Chief Source Type: research

Low serum potassium levels are associated with the risk of atrial fibrillation.
CONCLUSION: We found that low serum potassium levels of less than 3.5 mmol/l are associted with increased risk of AF. PMID: 32723154 [PubMed - as supplied by publisher]
Source: Acta Cardiologica - July 30, 2020 Category: Cardiology Tags: Acta Cardiol Source Type: research

Implementation of Oral Anticoagulation Treatment Guidelines in Patients with Newly Diagnosed Atrial Fibrillation
CONCLUSION: Despite the increasing OAC treatment rates among high risk AF patients, mainly attributed to the expanding DOAC use, OAC treatment scope is still far from optimal.PMID:33982796 | DOI:10.1111/bcp.14899
Source: Clinical Colorectal Cancer - May 13, 2021 Category: Cancer & Oncology Authors: Anat Arbel Zomoroda Abu-Ful Meir Preis Shai Cohen Walid Saliba Source Type: research

Adherence to Oral Anticoagulant Medications
CONCLUSIONS: Adherence rates to OAC in chronic use among patients with chronic NAVF are high. Investing in OAC adherence may have a wider health impact than expected.PMID:34472234
Source: The Israel Medical Association Journal - September 2, 2021 Category: General Medicine Authors: Michal Shani Doron Comaneshter Alex Lustman Source Type: research

Pages: 1  2  3  4  5  6  7